JN
Jacob Van Naarden (EVP & Pres., Lilly Oncology) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in Eli Lilly and Company (LLY). Across 1 priced purchase filing, the average 21-session return was +16.5% from execution and +16.5% from disclosure (delay-adjusted; derived). The largest single filing was $647K of LLY (1,000 sh × $647.36, as filed), executed Aug 13 2025. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+16.5%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+16.5%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$647K
shares × price, as filed
Last traded
Aug 13 2025
Filed Aug 13 2025
Median ADV $3.8B across their filed names
Open performance→Volume by month
Buys $647K
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 24 months
Most traded names
LLYRecent filings
LLYPURCHASE
Eli Lilly and Company
View filing →
$647K1,000 sh × $647.36
Exec Aug 13 2025
Filed Aug 13 2025 · 4:15 PM ET